<?xml version="1.0" encoding="UTF-8"?>
<p id="p0240">Of note, although the SARS-CoV-2 may use cathepsin B/L or TMPRSS2 for proteolytic priming (see 
 <xref rid="f0010" ref-type="fig">Fig. 2</xref>), only TMPRSS2 is essential for viral spread and pathogenicity (cathepsin B/L activity being dispensable) 
 <xref rid="b0445" ref-type="bibr">[89]</xref>, 
 <xref rid="b0440" ref-type="bibr">[88]</xref>, 
 <xref rid="b0450" ref-type="bibr">[90]</xref>. In this regard, it has been demonstrated that the transient expression of TMPRSS2 in Vero cells favors the cathepsin-independent entry of SARS-CoV-2. Furthermore, the pre-treatment of human Caco-2 colon and human airway cells with TMPRSS2 inhibitors reduces the entry of SARS-CoV-2 
 <xref rid="b0420" ref-type="bibr">[84]</xref>, 
 <xref rid="b0075" ref-type="bibr">[15]</xref>, 
 <xref rid="b0095" ref-type="bibr">[19]</xref>.
</p>
